Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally active, direct-acting P2Y12 receptor antagonist. It is a reversible, competitive inhibitor of ADP binding to the P2Y12 receptor on platelets.
## Primary Indications
* **Acute Coronary Syndrome (ACS):** To reduce the rate of cardiovascular thrombotic events, including stent thrombosis, in patients with ACS managed with percutaneous coronary intervention (PCI).
* **Myocardial Infarction (MI):** In patients with a history of MI, ticagrelor is indicated to reduce the rate of cardiovascular death, MI, stroke, and all-cause mortality.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months. In some patients, particularly those with a history of MI, therapy may be extended beyond 12 months.
* **History of MI (at least 1 year post-MI):**
* **Maintenance Dose:** 60 mg orally twice daily.
## Pediatric Dosing
Ticagrelor is not approved for use in pediatric patients.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is required in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is required in patients with mild, moderate, or severe renal impairment.
## Contraindications
* Active pathological bleeding (e.g., intracranial hemorrhage, gastrointestinal bleeding).
* History of transient ischemic attack (TIA) or stroke.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Common:** Dyspnea, bleeding (including fatal and life-threatening), contusion, rash.
* **Serious:** Major bleeding, ventricular pauses.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor plasma concentrations. Coadministration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor plasma concentrations.
* **Aspirin:** Concurrent use with aspirin increases the risk of bleeding. Maintenance doses of aspirin beyond the loading dose are not recommended in patients on ticagrelor.
* **Other Antiplatelets/Anticoagulants:** Concomitant use with other antiplatelet agents or anticoagulants increases the risk of bleeding.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Ventricular Pauses:** Observe for potential bradycardia, especially in patients with underlying risks.
## Clinical Pearls
* Ticagrelor is a direct-acting, reversible P2Y12 inhibitor, providing more rapid and consistent platelet inhibition compared to clopidogrel.
* Dyspnea is a common side effect and is typically mild and transient, not indicative of underlying cardiac or pulmonary disease.
* Discontinuation of ticagrelor should be avoided unless absolutely necessary due to increased risk of thrombotic events.
* If ticagrelor must be stopped temporarily for surgery, resume as soon as possible.
***
*This information is intended for healthcare professionals. Please consult the official prescribing information for complete details and to ensure adherence to current guidelines.*
